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Hugs vs. Drugs
How zebrafish and the science of social attachment can help us understand America’s opioid epidemic
By Eduardo Vargas

Setting The Stage

T

he United States has a problem with drugs — specifically a $78.5 billion opioid drug
problem. Legally available only by
a physician’s prescription, many
synthetic opioids such as oxycodone (Percocet) and hydrocodone (Vicodin) are used to mitigate moderate to severe pain, and
in 2015 they were prescribed to
around 38% of American adults.1
Just last year, one in eight patients
were shown to misuse prescription
opioids, and of approximately one

million opioid overdoses, 64,000
resulted in death.2 A study by the
University of Pittsburgh in October 2017 identified how different
demographic subsets of the population are affected by the opioid
crisis (Fig. 1). These sub epidemic
statistics show that there is a soaring death toll caused by fentanyl.
These studies also report that contrary to the popular media narrative of the average overdose victim being middle-aged, rural, and
white, fentanyl and heroin victims
are actually younger, urban, and
more racially diverse.3 Additional-

Figure 1 Data collected by the CDC displaying death rates by overdose of different
opioid types. Not pictured is data from 2016-17, which shows that deaths from other
synthetic opioids such as fentanyl have far surpassed prescription-based overdose.2
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ly, it has been reported that most
victims are not chronic pain patients themselves but friends or
family of patients that obtain pills,
with some reports of people taking
veterinarian-prescribed medicine
from their pets.4
To tackle this massive epidemic, over the last couple of
years the FDA has supported new
proactive solutions to drug addiction aimed at preventing abuse
of prescribed opioid analgesics to
reduce the impact of drug abuse
on American individuals and families. Among these initiatives is
the push for more widespread use
of non-opioid painkillers, prioritizing the development of “additional alternative medications that
alleviate pain but do not have the
addictive properties of opioids”.5
Although the problem has been
clearly identified, both the impact on health and the economic
fallout are increasing the need for
comprehensive approaches to addiction treatment, and scientists
are racing to find the multi-billion
dollar solution. To understand the
behaviors of addiction in humans,
many drug studies on animal models have begun to show promise
for understanding the underlying
mechanisms of addictive behavior,
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and zebrafish provide interesting
opportunities for this kind of research.

The Case for Zebrafish
Neuropharmacologic
research
of drugs often relies on animals
to model the behaviors induced
by the drugs in question, and zebrafish (Danio rerio) happen to be
good behavioral models. Sometimes referred to as the ‘new lab
mouse,’ zebrafish are relatively
easy to raise in large quantities,
can be modified genetically, and
have neural mechanisms that respond to drugs in similar ways as
human mechanisms (Fig. 2). With
a 70% similarity in their genome
to humans, zebrafish brains conserve the dopaminergic and glutamatergic projections involved
in reward pathways found in humans, and display the same μ-opioid receptors that interact with
the synthetic opioid drugs such
as hydrocodone.6 More than just
having the same cellular and molecular underpinnings, zebrafish
are also capable of displaying behavioral hallmarks of addiction to

Figure 2 The zebrafish (Danio rerio) is
a type of tropical freshwater minnow,
averages around 4 cm in length, and has
lateral stripes of pigmentation. Their
genome has been fully sequenced, making them ideal for genetic studies and
manipulation. Image taken by NICHD,
licensed by CC BY 2.0.

drugs. Among these hallmarks of
addiction are differences in various
swimming behaviors and social
group behaviors.
The best evidence to support zebrafish as relevant addiction models was found in August
2017 at the University of Utah
by researchers who developed an
opioid self-administration assay
using zebrafish.7 First, the zebrafish were trained to swim over one
of two active squares in their tank
to trigger a food reward. Paired
with a light cue, the trigger was
activated by camera that detected the zebrafish swimming above
the correct square. The zebrafish
could not randomly swim over
the active platform, since a computer would calculate whether the
zebrafish were swimming above
the platform more than a pre-programmed threshold. Once the
zebrafish were trained to use this
trigger mechanism, the researchers tested whether they would do
the same if the trigger released an
opioid drug instead of food. Their
results showed that the zebrafish
would consistently swim over the
drug active platform, even when
the zebrafish were given obstacles
to the task. For example, the researchers attempted to keep the
fish from activating the platform
by placing it at an uncomfortably
shallow level in the tank, but the
fish still swam over it to receive
the drug. They performed another
test in which the fish would have
to progressively activate the camera an increasing number of times,
and the fish were still more likely
to continue to trigger the platform
until the drug was released. The

researchers, Dr. Gabriel Bossé &
Dr. Randall T. Peterson, claim that
this is indicative of drug-seeking
behaviors, especially given that the
zebrafish were displaying characteristics that resemble addiction.
The zebrafish had to actively perform a specific behavior to secure
the drug, and after long term exposure they would show heightened anxiety as measured by a reduction in exploratory behavior.
To ensure that their findings were a direct result of the
drug, the researchers also tested
whether the same behaviors were
observed when the zebrafish were
treated separately with naloxone
(an opioid drug antagonist), and
NMDA and dopamine receptor
antagonists which would effectively stop the reward pathways. Their
findings were consistent with what
was expected, and in all three cases
the treatment effectively removed
the zebrafish’s preference to activate the drug-releasing platform.
In the final part of the
study, zebrafish had been pre-exposed to hydrocodone and were
essentially made addicted to it. The
behavior of this treatment group
was tested against a naive group
that had not been exposed to any
kind of drug, but was trained to
use the triggering mechanism.
The dependent variable measured
was each group of zebrafish’s social cohesion, or shoaling (Fig. 3).
Like many other fish, zebrafish
are known to form shoals in the
wild for various benefits, such as
procuring food in new environments. Shoaling has been identified as a potential social behavior
in zebrafish, so the researchers
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Figure 3 Forming shoals provides
zebrafish with many fitness advantages,
including safety from predation, exploration of novel environments, and recovery
of food. “Zebra Fish” by Oregon State
University is licensed by CC BY-SA 2.0.

sought to compare how the behavior changed when groups were
affected by opioid exposure.8 By
measuring the space in between
each fish with computer tracking,
they found that the zebrafish that
had been preconditioned with
hydrocodone but were no longer
exposed to it displayed more anxious behavior and a closer, tighter
shoaling group indicative of withdrawal. By contrast, the group that
wasn’t exposed to hydrocodone
in the long term formed a looser
shoaling group, and displayed generally more exploratory behavior.
The findings of this study
provide strong evidence for zebrafish as a bona fide model for
studying drug addiction. But as
concrete as the evidence is for zebrafish to experience addiction and
withdrawal to opioids, how much
of this information can inform our
understanding of drug-seeking behavior in humans?

How Opioid Addiction
Works

130

The neural mechanisms of addiction are well studied, especially
the pharmacokinetics of drugs of
abuse involving the dopaminergic
projections in the brain. An opioid
analgesic drug such as oxycodone
will act on the three kinds of opioid receptors in both the peripheral and central nervous system:
the mu-, delta-, and kappa- opioid
receptors. These receptors already
naturally interact with endorphins
secreted as an endogenous form of
pain relief — these are the same
neurotransmitters responsible for
the oft cited ‘runner’s high’ —
and they function by blocking the
sensation of pain by reducing a
neuron’s excitability, preventing it
from firing an action potential.9
Opioid drugs act on the
same exact neuron receptors, and
have slightly different mechanisms
of action depending on where in
the synapse they act. Binding to
the pre-synaptic opioid receptor
of dopaminergic neurons increases the release of dopamine in the
synapse. As it activates the next
neuron in the dopaminergic reward pathway, it is experienced
as a pleasurable, euphoric sensation. When the opioid binds to
post-synaptic opioid receptor, it

Figure 4 Acetaminophen/oxycodone
pills, a combination of and opioid and
non-opioid, commonly pr scribed for
pain relief. Image by Michelle Tribe,
licensed by CC BY 2.0.

antagonizes several different receptors and prevents them from receiving neurotransmitters, meaning that when acting on neurons
and interneurons responsible for
nociception, it will reduce the sensation of pain.9 This is where the
drug’s medicinal properties come
from.
To repeat this high, opioid users will need to continually
take higher and higher drug doses, which is due to the plasticity
of neurons. Over a long period
of sustained drug intake, the increasing amounts of dopamine
present in the synapse causes the
neurons to increase the number of
auto-receptors to compensate for
the excess neurotransmitter. The
increase in auto-receptors means
that dopamine is more likely to be
taken back up into the cell, so it
will be removed form the synapse
at a normal rate, thus diminishing
the euphoric feeling. This change
in receptors available is the pharmacodynamic basis of tolerance
(Fig. 5). The user may then compensate for this change by increasing their intake, further increasing
their pharmacodynamic tolerance
to the drug and, if enough of the
drug is available, becoming dependent on it to the point of addiction. The spiral of addiction is continued because the user is avoiding
the adverse effects of withdrawal,
and continuing to seek the reward
associated with the drug intake experienced in the earlier stages of
drug abuse.
Although we understand
how tolerance and addiction go
hand in hand at the molecular, cellular level, and behavioral level, not
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as much attention has been given
to the environment surrounding
the person suffering from opioid
addiction. As the more widely accepted behavioral model of alcoholism suggests, when looking at
addiction treatments we should
not only look at biological and
genetic mechanisms that facilitate
addiction, we should also take into
account the interactions between
the individual’s behavior, their
biology, and their environment.
One potential gap that remains to
be filled in the opioid crisis is an
understanding of the relationship
between addiction and social attachment, and zebrafish may help
us study the extent to which addiction is a product of biology and
the extent to which it is a product
of a person’s social environment.
Since previous research has already
established the hallmarks of the

Figure 5 Pharmacodynamic tolerance
occurs when a neuron compensates for
the effects of a drug by increasing or
decreasing the number of receptors available for the neurotransmitters involved.
Here, dopamine receptors are increasing
in response to the increased amount
of dopamine available in the synapse.
Image by National Institute on Drug
Abuse, licensed by Public Domain.

zebrafish’s social and addictive behavior, there is opportunity to use
these animal models to test out
different interactions between the
social environment and the chronic effects of drugs.

Addiction as a Form of
Social Attachment
We can take a look at this exact interaction by looking at how social
attachment and oxytocin can protect against addiction and stress.
Oxytocin is a type of neuropeptide
and hormone that, while implicated in many brain activities, is paramount to successful pair-bonding,
such as a mother-child bond, or
lifelong monogamous pair-bonding in voles.10 In these social interactions heavily involved in
reproductive success, oxytocin
receptors become up-regulated as
oxytocin availability increases.11
Oxytocin has also been implicated in learning and memory, which
has led some researchers to explore
how it affects the “learning and
memory processes involved in the
mechanism by which the addictive drug maintains control over
behavior”.12 While relatively little
is known about the direct mechanisms through which it could
affect addiction, research on oxytocin has found that it does have
a measurable effect on addiction.
One review of the literature found
that, regarding oxytocin, “in general, when the social interactions
occur outside of the drug-taking
context, positive, prosocial interactions are protective against drug
abuse-related behaviors, whereas social stressors facilitate these

behaviors”.12 In other words, the
presence of oxytocin can indicate a
social reward that can, to some extent, mitigate or even suppress the
reward of a drug-induced high.
Researchers at VU University Amsterdam further explored
the affiliative aspect of oxytocin,
and examine further evidence for
its palliative effects on addiction
processes. As it is heavily involved
in the formation of social bonds,
oxytocin specifically “is thought
to increase interpersonal trust, to
reduce stress responses, and to increase resilience, while protecting
against drug addiction and negative health effects of stress”.13 Their
research centers on the theory that
when people or other social beings
forge close and supportive social
relationships, they shift from novelty-and reward-seeking behaviors
to an appreciation of familiarity.13
The researchers attribute this shift
to the ventral and dorsal corticostriatal systems of the brain. The
corticostriatal pathway is a reward
circuit in the brain in which the
striatum receives the dopaminergic and glutamatergic signals mentioned previously. According to
the researchers, the positive and
euphoric rewards produced by
novel experiences corresponds to
heightened dopaminergic activity in the ventral striatum pathway, and it occurs when new social bonds are being formed. The
dorsal striatum pathway becomes
involved when the novelty seeking
behavior begins to shift from impulsivity to compulsivity.13 These
pathways can also apply to when
an individual is exposed to rewarding drug effects. At first, rec-
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reational use of a drug falls in line
with the novelty-seeking behavior
supported by the ventral pathway,
but over time, as the user begins to
seek out the drug out of compulsion to escape effects of withdrawal, their attachment to the drug is
maintained by the dorsal pathway.
These explanations of the behavioral underpinnings of addiction
suggest that a lack of social attachment can increase sensitivity to
drug addiction.
In mice studies, individuals experiencing various forms of
stress were more likely to become
addicted to drugs.12 It is easy to
imagine how this can apply to humans as well. We are familiar with
the narrative of individuals dealing
with economic hardship or social
isolation finding it easier to fall
into the downward spiral of addiction. Thinking of these behaviors
in terms of brain pathways can
give us a more nuanced picture of
how an individual’s social bonds
and environment can have an impact on addictive behavior. We can
begin to change our understanding
of addiction as a strictly biological
disease to include a model of addiction as a form of social attachment. If the presence of oxytocin
stemming from strong pro-social
bonds protects from stress and addiction, then what does this mean
for how we approach addiction
treatments moving forward?

The Future of Addiction
Treatment
The biosocial understanding of
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how opioid addiction functions
can have profound implications for
how we approach addiction treatments. In fact, the authors of the
study from Amsterdam University
urge other scientists to apply their
findings to animal models of addiction. The zebrafish model could
be a useful organism to use for this
type of research. As the self-administration assay showed, they
can display hallmarks of social, addiction, and withdrawal behaviors,
so they may prove useful in for exploring how social attachment and
cohesion play a role in addiction.
They could even help scientists
come up with novel, holistic solutions to treating addiction.
The rise in opioid overdose
victims has already pushed physicians to research new treatments
for addiction. Cannabis, for example, is gaining popularity as a
treatment since it helps victims
come off of their opioids without experiencing the debilitating
effects of withdrawal. In some
cases, other drugs such as weaker
opioid derivatives have been used
for a similar purpose, but with less
promising results. What might
treatment look like if we can take
a more interdisciplinary approach
to treating a person’s addiction? It’s
possible for the answer to be hidden in zebrafish, or another viable
animal model. While the solutions
remain varied and elusive, the concrete reality is one: the opioid crisis
is one of our generations biggest
unforeseen problems, and it will
require concerted contributions
from many fields before we start
seeing positive results of a similar
magnitude.
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